Drug Profile
ToleriMab
Alternative Names: anti-B7.1 Mab + anti-B7.2 MabLatest Information Update: 13 Sep 2001
Price :
$50
*
At a glance
- Originator Innogenetics
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 13 Sep 2001 Discontinued-Preclinical for Transplant rejection in Netherlands (Unknown route)
- 05 Oct 2000 Innogentics has the intention to partner with biopharmceutical companies for the programme
- 15 Jan 1999 Preclinical development for Transplant rejection in Netherlands (Unknown route)